Therapeutic applications of toll-like receptors (TLRs) agonists in AML

被引:3
|
作者
Peng, Ye [1 ]
Wang, Yanzhong [2 ]
Wang, Manling [1 ]
Lan, Jianping [1 ]
Chen, Yirui [1 ]
机构
[1] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Canc Ctr,Dept Hematol, 58 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Clin Lab, Sch Med, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2022年 / 24卷 / 12期
基金
中国国家自然科学基金;
关键词
AML; TLR; Leukemia; Immunotherapy; Hematological malignancy; SQUAMOUS-CELL CARCINOMA; ACUTE MYELOID-LEUKEMIA; DC MATURATION; PHASE-I; CANCER; ACTIVATION; TOLL-LIKE-RECEPTOR-2; EXPRESSION; RESISTANCE; INDUCTION;
D O I
10.1007/s12094-022-02917-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) is an aggressive type of blood cancer affecting bone marrow (BM). In AML, hematopoietic precursors are arrested in the early stages of development and are defined as the presence of >= 20% blasts (leukemia cells) in the BM. Toll-like receptors (TLR) are major groups of pattern recognition receptors expressed by almost all innate immune cells that enable them to detect a wide range of pathogen-associated molecular patterns and damage-associated molecular patterns to prime immune responses toward adaptive immunity. Because TLRs are commonly expressed on transformed immune system cells (ranging from blasts to memory cells), they can be a potential option for developing efficient clinical alternatives in hematologic tumors. This is because several in vitro and in vivo investigations have demonstrated that TLR signaling increased the immunogenicity of AML cells, making them more vulnerable to T cell-mediated invasion. This study aimed to review the current knowledge in this field and provide some insight into the therapeutic potentials of TLRs in AML.
引用
收藏
页码:2319 / 2329
页数:11
相关论文
empty
未找到相关数据